SCOTTSDALE, Ariz., July 21 /PRNewswire/ — MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for anxiety and depression therapies.
In this report, entitled “MedPredict Thought Leader Insight & Analysis: Anxiety & Depression Q3 2008,” a panel of physician experts from North America and Europe discuss the strengths and weaknesses of a variety of branded and near-market antidepressants and anxiolytics.
“In our last report we highlighted three key unmet needs — higher core efficacy, more durable remissions and lower side effects,” said Dr. Jeffery Berk, MedPredict’s president and one of the authors of the report. “This new report identifies the characteristics that next-generation therapeutics will need to go beyond those benefits and deliver enhanced cognition, reduced anhedonia, and relief from pain and fatigue.” Some of the questions addressed by MedPredict’s panel:
— How will FDA’s approval of Lilly’s Cymbalta for neuropathic diabetic pain and fibromyalgia impact its use in depression? How important is a pain indication in treatment of depression?
— In this challenging regulatory and economic environment, what will new therapeutics need to demonstrate to displace current usage of SSRIs, SRNIs and generic antidepressants? How should these studies be designed?
— How do thought leaders view the strengths and weaknesses of Lilly’s Cymbalta vs. Wyeth’s Pristiq?
— What are the differences in prescribing trends among psychiatrists compared with primary care physicians?
— Which of the new molecules and mechanisms in development are most promising? The panel covers triple reuptake inhibitors, antipsychotics, MAOIs, Beta-3 agonists, nicotinic acetylcholine receptor agonists, NMDA/glutamatergics, GABA, CRH and more.
Companies/Partnerships discussed include: Abbott, AstraZeneca, Bristol-Myers Squibb, Forest/Lundbeck, Forest/Cypress/Pierre Fabre, Lilly, Lilly/Boehringer Ingelheim, Lundbeck/Takeda, Merck-Serono, Ono, Novartis/Servier, Pfizer, Sanofi-Aventis, Sepracor, Targacept/AstraZeneca, Wyeth, and others.
This report can be purchased by contacting MedPredict. About MedPredict
MedPredict (http://www.medpredict.com/) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
MedPredict
CONTACT: Elizabeth Mathews of MedPredict, +1-513-271-1924,[email protected]
Web site: http://www.medpredict.com/
Comments